Cytosorbents Corporation - Common Stock (CTSO)

As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

CytoSorbents (CTSO) reported Q2 2025 results with revenue of $9.62M, beating estimates, and a narrower EPS loss of -$0.05. Shares rose 4.32% post-earnings amid steady demand for CytoSorb.

Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.

CytoSorbents is progressing with U.S. FDA and Health Canada reviews for its DrugSorb-ATR device.

CTSO stock results show that CytoSorbents beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

CytoSorbents shares are trading higher by 20% during Tuesday's session. The company entered into a new $20 million credit facility with Avenue Capital Group.